
Foghorn Therapeutics Inc.
NASDAQ:FHTX

Intrinsic Value
The intrinsic value of one
FHTX
stock under the Base Case scenario is
4.95
USD.
Compared to the current market price of 4.87 USD,
Foghorn Therapeutics Inc.
is
Undervalued by 2%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Foghorn Therapeutics Inc.
Loading...
Fundamental Analysis


Revenue & Expenses Breakdown
Foghorn Therapeutics Inc.
Balance Sheet Decomposition
Foghorn Therapeutics Inc.
Current Assets | 203.8m |
Cash & Short-Term Investments | 198.7m |
Other Current Assets | 5.2m |
Non-Current Assets | 22.4m |
PP&E | 20.4m |
Other Non-Current Assets | 2m |
Free Cash Flow Analysis
Foghorn Therapeutics Inc.
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Foghorn Therapeutics Inc.
Revenue
|
24.2m
USD
|
Operating Expenses
|
-116m
USD
|
Operating Income
|
-91.9m
USD
|
Other Expenses
|
16.5m
USD
|
Net Income
|
-75.4m
USD
|
FHTX Profitability Score
Profitability Due Diligence
Foghorn Therapeutics Inc.'s profitability score is 38/100. The higher the profitability score, the more profitable the company is.

Score
Foghorn Therapeutics Inc.'s profitability score is 38/100. The higher the profitability score, the more profitable the company is.
FHTX Solvency Score
Solvency Due Diligence
Foghorn Therapeutics Inc.'s solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Score
Foghorn Therapeutics Inc.'s solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FHTX Price Targets Summary
Foghorn Therapeutics Inc.
According to Wall Street analysts, the average 1-year price target for
FHTX
is 11.9 USD
with a low forecast of 9.09 USD and a high forecast of 14.7 USD.
Dividends
Current shareholder yield for FHTX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
FHTX
stock under the Base Case scenario is
4.95
USD.
Compared to the current market price of 4.87 USD,
Foghorn Therapeutics Inc.
is
Undervalued by 2%.